Oblongifolin M, an active compound isolated from a Chinese Medical herb Garcinia oblongifolia, potently inhibits Enterovirus 71 reproduction through downregulation of ERp57 by Chen, X et al.
Title
Oblongifolin M, an active compound isolated from a Chinese
Medical herb Garcinia oblongifolia, potently inhibits Enterovirus
71 reproduction through downregulation of ERp57
Author(s)
Wang, M; Dong, Q; Wang, H; He, Y; Chen, Y; Zhang, H; Wu, R;
Chen, X; Zhou, B; He, J; Kung, HF; Huang, C; Wei, Y; Huang, J;
Xu, H; He, ML
Citation Oncotarget, 2016, v. 7 n. 8, p. 8797-8808
Issued Date 2016
URL http://hdl.handle.net/10722/248313
Rights This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Oncotarget8797www.impactjournals.com/oncotarget
www.impactjournals.com/oncotarget/ Oncotarget, Vol. 7, No. 8
 Oblongifolin M, an active compound isolated from a Chinese 
medical herb Garcinia oblongifolia, potently inhibits enterovirus 
71 reproduction through downregulation of ERp57 
 Mengjie Wang 1, 2, * , Qi Dong 2, 3, 9,* , Hua Wang 3 , Yaqing He 4 , Ying Chen 9 , Hong Zhang 1 , 
Rong Wu 1 , Xinchun Chen 5 , Boping Zhou 5 , Jason He 8 , Hsiang-Fu Kung 2, 3 , Canhua 
Huang 6 , Yuquan Wei 6 , Jian-dong Huang 7 , Hongxi Xu 1 , Ming-Liang He 9 
 1 School of Pharmacy, Shanghai University of Traditional Chinese Medicine, Shanghai, China 
 2 Shenzhen Research Institute, The Chinese University of Hong Kong, Shenzhen, China 
 3 Stanley Ho Center for Emerging Infectious Diseases, The Chinese University of Hong Kong, Hong Kong, China 
 4 Shenzhen Center for Disease Control and Prevention (Shenzhen CDC), Shenzhen, China 
 5 Institute of Infectious Diseases, The 3rd Peoples’ Hospital of Shenzhen, Shenzhen, China 
 6 State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University , Chengdu, China
 7 School of Biomedical Sciences, The University of Hong Kong, Hong Kong, China 
 8 College of Letter and Sciences, University of California at Berkeley, Berkeley, CA, USA 
 9 Department of Biomedical Sciences, City University of Hong Kong, Hong Kong, China 
 * These authors have contributed equally to this work 
 Correspondence to:  Ming-Liang He, e-mail:  mlhe7788@gmail.com
 Hongxi Xu, e-mail:  xuhongxi88@gmail.com 
 Keywords: enterovirus 71, Oblongifolin M, ERp57, antiviral 
 Received: October 09, 2015     Accepted: January 19, 2016     Published: February 01, 2016 
 ABSTRACT 
 There is no effective drug to treat EV71 infection yet. Traditional Chinese herbs 
are great resources for novel antiviral compounds. Here we showed that  Oblongifolin 
M (OM), an active compound isolated from  Garcinia oblongifolia , potently inhibited 
EV71 infection in a dose dependent manner. To identify its potential effectors in the 
host cells, we successfully identiﬁ ed 18 proteins from 52 differentially expressed 
spots by comparative proteomics studies. Further studies showed that knockdown of 
ERp57 inhibited viral replication through downregulating viral IRES (internal ribosome 
entry site) activities, whereas ectopic expression of ERp57 increased IRES activity 
and partly rescued the inhibitory effects of OM on viral replication. We demonstrated 
that OM is an effective antiviral agent; and that ERp57 is one of its cellular effectors 
against EV71 infection. 
 INTRODUCTION 
 Enterovirus 71 (EV71), a member of the 
 Picornaviridae family, is a non-enveloped single-
stranded RNA virus. It is the major causative agent of 
repeated outbreaks of hand, foot and mouth disease 
(HFMD) [ 1 ,  2 ]. In severe cases, especially those among 
in infants and children, EV71 infection causes severe 
neurological complications such as aseptic meningitis, 
brain stem encephalitis, pulmonary edema, poliomyelitis-
like paralysis and eventual death. In the last decade, the 
continuous outbreaks of EV71 in Asia-Paciﬁ c region 
have caused considerable deaths [ 3 ]. More than 7 million 
HFMD cases were reported in China between 2008 
and 2012, of which 2457 were fatal [ 4 ,  5 ]. No effective 
antiviral drug is currently used for treating EV71 infection 
[ 6 ]; therefore, there is an urgent need for effective agent 
against EV71 infection. 
 Chinese Medical herbs are a great reservoir of active 
compounds against microbial infections [ 7 – 14 ]. Plants 
generate a great deal of compounds to eliminate or limit 
microbe invasions. The family  Guttiferae contains more 
than 450 species distributed over regions mostly in Asia, 
southern Africa and Western Polynesia. Many bioactive 
compounds, such as prenylated xanthenes, benzophenones, 
biﬂ avonoids, and polycyclic polyprenylated 
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acylphloroglucinols, have been isolated from different 
family members [ 15 – 23 ]. They exhibit various biological 
activities including antibacterial, antifungal, antioxidant, 
anti-inﬂ ammatory and anticancer effects [ 15 – 23 ], despite 
the underlining mechanisms being poorly understood. 
 With the growing number of natural antiviral 
compounds identiﬁ ed, a promising option would be 
to ﬁ nd new compounds from medical herbs to combat 
EV71 infection [ 24 – 26 ]. Instructed by bioactivity-guided 
isolation, a new isoprenyl benzophenone derivative 
Oblongifolin M (compound M from  Oblongifolia , OM), 
has been isolated from medical herb  Garcinia oblongifolia 
[ 27 ]. In this study, we investigated its antiviral activity 
against EV71 infection and the underlying mechanisms 
through comparable proteomics studies. 
 RESULTS 
 Protection of cytopathic effects (CPE) caused by 
EV71 infection 
 The antiviral effect of OM was tested in 
Rhabdomyosarcoma (RD) cells by CPE assays. As shown 
in  Figure 1A , the RD cells without viral infection were ﬂ at 
with spindle-like sharps and attached well on the surface 
of culture dishes. When cells were infected with EV71 at 
a multiple of infection (MOI) of 1, many cells showed 
CPE. They became round, detached from the surface of 
culture dishes and ﬂ oated away 12 hours post-infection 
(p.i.) ( Figure 1B ). When the cells were pretreated with 15 
μM of OM 4 hours prior to EV71 infection, most cells 
were healthy with only a few exhibiting CPE ( Figure 1C ), 
an indication that the infected cells were signiﬁ cantly 
protected from CPE. Surprisingly, almost all EV71-
infected cells were healthy when pretreated with 30 μM 
of OM ( Figure 1D ). Similar results were also obtained 
from HEK 293 cells and Hela cells (data not shown). 
The reduction of EV71-induced CPE by 50% (IC 50 ) was 
determined byusing GraphPad Prism5. As shown in  Table 
1 , the IC 50 of OM was 2.38±0.79 μM. Cell viability was 
employed to determine the toxicity of OM in RD cells 
by MTT (3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2-H-
tetrazolium bromide) assays after treating RD cells with 
OM for 24h. Compared with untreated cells, cell viability 
was not obviously affected by OM at a concentration 
of 50 μM. The CC 50 (concentration of OM required for 
50% cell kill) of the uninfected cells was 83.87±1.12 μM. 
The selectivity of OM on RD cells was 35.24 ( Table 1 ), 
indicating OM’s potential to be an effective antiviral agent 
against EV71 infection. 
 Figure 1: The inhibitory effects of OM against EV71 infection OM protected cytotoxic effects (CPE) from EV71 infection in 
RD cells  A. to  D . RD cells were pretreated without  (A, B) or with OM  (C, D) for 4 hours before EV71 infection at a MOI of 1. Photos were taken 
12 hours post-infection (p.i.).  E. OM inhibited EV71 reproduction. The virions in the culture supernatant were harvested 12 hours p.i. and the viral 
titer was determined by TCID 50 assays.  F. OM inhibited EV71 replication. 12 hous p.i., the intracellular RNA was isolated, and viral genomic RNA 
(primers targeting VP1 gene) and cellular mRNA of GAPDH genes were quantitated by qRT-PCR. The viral genomic RNA level was normalized 
with the copy number of mRNA of GAPHD. The mean value of VP1/GAPDH ratio was set as 1 in control.  G. The viral VP1 protein was decreased 
by OM in a dose dependent manner. The cells were harvested 12 hours p.i. at MOI of 1, and cell lysate was applied for Western blot assays. 
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 Inhibition of EV71 propagation 
 To further determine OM’s antiviral potency, we 
titrated the viral titers in the culture media. As shown in 
 Figure 1E , the mean value of viral titers was 5.6 × 10 6 pfu/
ml in the control group. After treatment of the cells with 15 
μM of OM, the viral titers signiﬁ cantly decreased to 3.42 × 
10 6 ± 6.4 × 10 5 pfu/ml. When the concentration of OM was 
increased to 30 μM, surprisingly, the viral titers dramatically 
dropped by over 90% to 2.5 × 10 5 ± 1.1 × 10 5 pfu/ml. The 
antiviral effects were further validated by measuring the 
intracellular viral genomic RNA copies and viral protein 
levels. Twelve hours after infection, the copy number of 
viral genomic RNA decreased by 23%, 65%, 84% and 95% 
after cells were treated with OM at concentrations of 15, 
20, 25, and 30 μM, respectively ( Figure 1F ). Consistently, 
the levels of intracellular VP1 protein were signiﬁ cantly 
inhibited by OM in a dose dependent manner ( Figure 1G ). 
 The effects of OM on protein proﬁ les 
 To investigate the potential antiviral mechanisms 
of OM against EV71 infection, we employed comparable 
proteomics studies. Proteins from RD cells treated with 
DMSO (control) or 30 μM of OM were extracted and 
resolved by 2-DE analysis 48 hours post-treatment.  Figure 
2 shows a representative pair of silver-stained 2-DE maps 
between two samples from three pairs of gels ( Figure 2A and 
 2B ). After comparison, 52 spots showed signiﬁ cant (with 
over 2-fold, p < 0.05) difference. The individual protein 
spot was extracted and digested for MALD-TOF MS and 
MS/MS analysis. Typical images of ﬁ ve paired spots were 
cropped and enlarged as shown in  Figure 2C . We successfully 
identiﬁ ed 18 proteins with signiﬁ cant differential expression. 
Among them, eight proteins were markedly up-regulated 
whereas ten were down-regulated in the OM-treated RD 
cells as compared to the control group. The characteristics 
of proteins (including name, abbreviation, NCBI accession 
number, theoretical molecular mass, pI, peptide count, protein 
score (conﬁ dence interval in percent), number of unmatched 
masses, sequence coverage, fold change, and functions) are 
listed in  Table 2 . Functionally, they can be categorized into six 
categories: structural molecular activity (17%), metabolism 
(39%), cytoskeleton and transport proteins (11%), gene 
transcription associated proteins (6%), heat shock proteins 
and chaperones (17%), and cell proliferation, metastasis, and 
signal transduction proteins (11%). 
 Table 1: Cytotoxic, antiviral activity and selectivity index of OM against EV71 
 Compound  Cytotoxicity  Antiviral activity a  Selectivity Index 
 OM  CC 50 (μM)  IC 50 (μM)  SI (CC 50 /IC 50 ) 
  83.87±1.12 b  2.38±0.79 b  35.24 
 a. RD cells were infected with EV71 at a MOI of 0.01 after treatment with serial dilution of OM for 4 h. 
 b. Values obtained from nonlinear regression analysis using GraphPad Prism5. 
 Values represent the mean ± SD of three independent experiments. 
 Figure 2: Protein proﬁ le differences between Control and OM-treated RD cells.  A. and  B. representative silver-stained 2-DE 
maps of proteins from DMSO and 30 μM of OM (resolved in DMSO) treated RD cells. Fifty two differential expressed spots were picked 
up for MALDI-TOF-MS and MS/MS analysis. The spots of eighteen differently expressed proteins identiﬁ ed were marked. C. The enlarged 
sections of the 2-DE map. Spot 4, RCN-3; spot 5, RCN-1; spot 6, calumenin; and spot 17, ERp57. 
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 Table 2: Differentially expressed proteins identiﬁ ed by 2-DE/MS analysis in RD cells treated without/with OM (At 
a 2-fold difference cutoff in intensity, xx spots were selected for further MALD-TOF-MS/MS analysis, 18 proteins 
were ﬁ nally identiﬁ ed) 
 Spots 
No. a 
 Protein name  Abbreviation  NCBI 
accession 
no. 
 Theoretical 
molecular 
mass(Da) 
 PI  Protein 
core (CI) 
 Masses 
matched/ 
searched 
 Sequence-
coverage 
(%) 
 ‘-Fold 
change b 
 Structural molecule activity 
 1  Rho-associated protein kinase 2  ROCK2  O75116  161939  5.75  69  9/13  5  11.7↓ 
 24  Prelamin-A/C  LMNA  P02545  74380  6.57  97  15/36  22  4.1↓ 
 26  Annexin A7  ANXA7  P20073  52991  5.52  71  8/21  15  3.7↑ 
 Metabolism 
 4  Reticulocalbin-3  RCN3  Q96D15  37470  4.74  94  8/27  32  18.2↓ 
 5  Reticulocalbin-1  RCN1  Q15293  38866  4.86  115  12/34  34  15.3↓ 
 6  Calumenin  CALU  O43852  37198  4.47  80  9/30  26  4.3↓ 
 7  Proteasome subunit alpha type-3  PSMA3  P25788  28643  5.19  60  6/26  20  3.8↑ 
 15 
 N(G),N(G)-
dimethylarginine 
dimethylamino-
hydrolase 2 
 DDAH2  O95865  29911  5.66  59  6/28  18  3.6↑ 
 21  Mitochondrial inner membrane protein  IMMT  Q16891  84025  6.08  117  14/28  16  3.3↓ 
 37 
 26S protease 
regulatory subunit 
10B 
 PSMC6  P62333  44430  7.1  58  6/14  13  3.3↑ 
 Cytoskeleton and transport proteins 
 8  Actin, cytoplasmic 1  ACTB  P60709  42052  5.29  111  9/29  26  3.8↑ 
 22  Vinculin  VCL  P18206  124292  5.5  96  14/27  11  3.0↑ 
 Gene transcription 
 39 
 Far upstream 
element-binding 
protein 1 
 FUBP1  Q96AE4  67690  7.18  110  11/21  17  3.1↑ 
 Heat shock proteins and chaperones 
 17  Protein disulﬁ de-isomerase A3  ERp57  P30101  57146  5.98  76  11/31  17  13↓ 
 18  T-complex protein 1 subunit alpha  TCP1  P17987  60819  5.8  77  9/24  16  3.4↓ 
 27  T-complex protein 1 subunit beta  CCT2  P78371  57794  6.01  121  13/29  22  3.9↓ 
 Cell proliferation, metastasis, and signal transduction 
 33  Septin-11  SEPT11  Q9NVA2  49652  6.36  114  12/22  22  8.5↑ 
 34  Fascin  FSCN1  Q16658  55123  6.84  103  10/24  18  10.8↓ 
a Spot numbers are shown in  Figure 2 . 
b The spot intensities were quantiﬁ ed using PDQuest software (Bio-Rad). The average -fold change of spot intensity for each 
protein was calculated from three independent experiments (DMSO-treated RD versus OM-treated RD). ↑, increase; ↓, decrease. 
Oncotarget8801www.impactjournals.com/oncotarget
 Validation of differentially expressed protein by 
western blot assay 
 We carried out Western blot assays to conﬁ rm the 
differentially expressed protein levels after we treated 
the RD cells with OM for 48 hours. Among ﬁ ve selected 
candidate proteins, four displayed similar expression 
patterns as shown in the 2-DE assays. The protein levels 
of ERp57, RCN-1, RCN-3, and CALU signiﬁ cantly 
decreased after OM treatment ( Figure 3A ). 
 ERp57 drew our particular attention because it is 
crucial for the entry of SV40 and murine rotavirus [ 28 ,  29 ]. 
To further observe the correlation between the expression 
levels of ERp57 and EV71 viral proteins, RD cells were 
treated with or without 30 μM of OM for 4 hours, and 
then infected with EV71 (MOI 1). As shown in  Figure 
3B , OM not only suppressed ERp57 expression, but also 
signiﬁ cantly decreased viral VP1 and VP2 levels. These 
results indicated that ERp57 might involve the life cycle 
of EV71. 
 Suppression of EV71 by knockdown of ERp57 
 We tested the effects of ERp57 knockdown on EV71 
infections. As shown in  Figure 4A , both si-ERp57-1 and 
ERp57-2 effectively reduced the mRNA level of ERp57. As 
si-ERp57-1 was more effective on knocking down ERp57, 
si-ERp57-1 was chosen for further experiments in our study. 
Consistent with the reduction of mRNA level, ERp57 protein 
level was also signiﬁ cantly decreased by si-ERp57-1 ( Figure 
4B ). We further examined if knockdown of ERp57 would 
affect virus entry. RD cells were ﬁ rst transfected with either 
scrambled or si-ERp57-1 for 48 hours, and then infected 
with EV71 at MOI of 20 for 1 hour on ice. The infected cells 
were washed with PBS for three times to remove potential 
free viruses that had not entered the cells. We employed 
qRT-PCR to measure the intracellular viral RNA levels. Our 
data showed that the entry of EV71 had not been affected 
by ERp57 knockdown ( Figure 4C ). To further investigate 
if ERp57 knockdown would affect EV71 replication or 
reproduction, we ﬁ rst measured the intracellular viral RNA 
levels at different time points. We showed that ERp57 
knockdown signiﬁ cantly decreased the intracellular viral 
RNA levels at 3 and 5 hours p.i. ( Figure 4D ), and markedly 
reduced the secreted virions in the culture media collected 
at 5 and 7 hours p.i. ( Figure 4E ). These results indicate that 
ERp57 was involved in the early phase of viral life cycle. 
 Inhibition of IRES activity by OM and ERp57 
 Our previous study showed that active replication 
of EV71 occurs just after uncoating (3 to 6 hours p.i.) 
[ 30 ]. After uncoating, the ﬁ rst and key event is viral 
protein translation driven by IRES [ 31 ]. Therefore, we 
hypothesized that OM may inhibit EV71 infection by 
down-regulation of IRES activity through ERp57. To test 
this hypothesis, we generated two constructs to express 
reporters  Renilla luciferase (RLuc) and  Fireﬂ y luciferase 
(FLuc). As shown in  Figure 5A , two continuous stop 
codes (TGA TGA) were inserted between RLuc and FLuc 
 Figure 3: The suppression of ERp57 expression by OM.  A. RD cells were treated with OM at 30 μM for 48 hours, and cell lysates 
were harvested and applied for Western blot assays. As shown, ERp57, RCN-1, RCN-2 and Calumenin were markedly down-regulated by 
OM treatment.  B. Cells were pretreated with 30 μM of OM for 4 hours, and then infected with EV71 at MOI of 1 for 12 hours. As shown, 
OM suppressed the expression of ERp57, and viral proteins VP1 and VP2. The relative density value of each band to GAPHD was set as 
1 in the control group. 
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genes in pRF plasmid; while the IRES sequence of EV71 
was inserted between RLuc and FLuc genes in pIRES 
plasmids. In both constructs, the CMV promoter drives 
RLuc expression. FLuc translation is stopped when mRNA 
is transcribed from pRF, whereas the translation would be 
successful from that of pIRES. Hence, the IRES activity 
can be measured and expressed by the ratio of FLuc to 
RLuc activities. 
 We showed that OM did not affect the ratio of FLuc/
RLuc when cells were transfected with pRF plasmid; 
however, the ratio of FLuc/RLuc decreased after cells 
were transfected with pIRES and treated with OM. The 
inhibition of IRES activity was in a dose-dependent 
manner ( Figure 5B ). As expected, when ERp57 was 
knocked down, the IRES activity of EV71 markedly 
decreased ( Figure 5C ), correlating with the inhibitory 
effects of OM. 
 Restoration of OM-suppressed IRES activity by 
ectopic expression of ERp57 
 We constructed an expression plasmid to express 
human ERp57 in HEK 293 cells. As shown in  Figure 6A , 
the ectopic expression of ERp57 signiﬁ cantly stimulated 
the IRES activity of EV71. Furthermore, we examined 
if ectopic expression of ERp57 would restore the viral 
replication that had been inhibited by OM. ERp57 was 
ectopically expressed in RD cells and pretreated with 
OM at 30 μM for 4 hours. The cells were then infected 
with EV71 at MOI 1. We showed that the viral RNA 
level decreased to 25% that of the control 5 hours p.i., 
whereas the viral RNA level was restored to that 53% of 
the control upon overexpression of ERp57. Our results 
demonstrated that ERp57 partly restored the IRES 
activity suppressed by OM. 
 Figure 4: Inhibition of EV71 infection by Knockdown of ERp57 at early stage .  A. Speciﬁ c siRNAs targeting ERp57 were 
transfected into RD cells, and the effect of knockdown was determined by qRT-PCR 48 hours post-transfection.  B. The ERp57 protein 
level detected by si-ERp57-1 knockdown.  C. Knockdown of ERp57 did not affect EV71 entry. Forty eight hours post-transfection with 
siRNAs, cells were infected with EV71 at MOI of 1 for 1 hour (time point was set as 0 hour), and cells were washed with PBS for three 
times. The intracellular viral RNA level was determined by qRT-PCR. The mean value of VP1/GAPDH ratio was set as 1 in control.  D.
and  E. The intracellular (D) and extracellular (E) viral RNA levels upon ERp57 knockdown at different time points. The total RNA was 
isolated from infected cells and corresponding media at different time points, and quantiﬁ ed by quantitative RT-PCR. At time point 0 hour, 
the intracellular viral RNA level (virions just entered the cells) were quantitated by qRT-PCR *,  p < 0.05; **,  p < 0.01; ***,  p < 0.001. 
Oncotarget8803www.impactjournals.com/oncotarget
 Figure 5: Inhibition of EV71 IRES activity by OM or knockdown of ERp57. A. Schematic diagram of plasmids pIRES and 
pRF for measuring IRES activity.  B. OM inhibited IRES activity in a dose dependent manner. Cells were transfected with pIRES or pRF for 
24 hours, and then treated without or with OM for 12 hour followed by luciferase assays.  C. Knockdown of ERp57 reduced IRES activity. 
Cells were transfected with scramble siRNA or si-ERp57-1. Twenty four hours post-transfection, the cells were then transfected with pIRES 
or pRF for another 24 hours and applied for luciferase assays. The ratio of FLuc to RLuc activity was set as 1 when cells were transfected 
with pRL reporter plasmid in the control group (without OM treatment or transfected with scrambled siRNA). *,  p < 0.05; ***,  p < 0.001. 
 Figure 6: Ectopic expression of ERp57 enhanced IRES activity.  A. Ectopic expression ERp57 increased the reporter expression 
driven by IRES;  B. Ectopic expression of ERp57 partly rescued OM’s inhibitory effect on IRES. **,  p < 0.01. 
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 DISCUSSION 
 There is no effective drug to treat EV71 
infection [ 31 – 33 ]. In this paper, we showed that an 
effective compound OM isolated from  Garcinia 
oblongifolia displayed potent anti-EV71 activitythrough 
downregulation of ERp57, an important host factor in the 
early phase of EV71 life cycle. 
 Host proteins are ideal targets for antiviral drug 
development because targeting host proteins would avoid 
or delay the occurrence of drug resistance due to fast 
mutagenesis of viruses. ERp57, a chaperon protein involved 
in catalyzing bisulfate bond exchange for correct protein 
folding in ER stress, has been shown a crucial role in the 
entry of DNA virus SV40 [ 28 ]. Besides virus entry, it is 
possible that ERp57 may exhibit other functions in the life 
cycle of other viruses. As an RNA virus, EV71 has a life 
cycle that is completely different from that of SV40. An 
important question is whether ERp57 exhibits a similar 
function in the life cycle of EV71. To address this question, 
we ﬁ rst investigated if the viral entry of EV71 would be 
affected by knockdown of ERp57. To our surprise, the 
depletion of ERp57 did not affect virus entry into the host 
cells ( Figure 4C ). Interestingly, we found that the virus 
replication was signiﬁ cantly suppressed at 3 to 5 hours p.i. 
after ERp57 knockdown in the host RD cells ( Figure 4D ). 
Accordingly, the secreted virions evidently decreased at 5 
to 7 hours p.i. ( Figure 4E ). In our previous study, we have 
shown that EV71 undergoes the fast replication phase from 
3 to 6 hours p.i. in RD cells, and carries out fast package 
from 6 to 9 hours p.i. (package phase) and secretion 
initiation [ 30 ]. Our results suggested that ERp57 involves 
mainly in the early phase of viral life cycle. 
 The ﬁ rst event of viral activity is IRES-mediated 
translation in generating proteins required for viral RNA 
replication after uncoating of virus in the host cells. We 
hypothesized that ERp57 may affect viral translation 
through regulating viral IRES activities. Our results 
showed that knockdown of ERp57 signiﬁ cantly reduced 
the viral IRES activities ( Figure 5B ). Intriguingly, OM 
also suppressed the IRES activity in a dose dependent 
manner ( Figure 5C ), demonstrating a correlation between 
drug effects and ERp57 functions. To further validate our 
ﬁ ndings, we conducted gain-of-function studies. ERp57 
was ectopically expressed in host cells to test its effects 
on IRES activity. As expected, results from this study 
exhibited an increase of IRES activity by ectopic ERp57 
expression ( Figure 6A ). This suggests that OM may 
affect ERp57 functions in an indirect or direct manner. 
We have noted that ectopic expression of ERp57 partly 
rescued the inhibition of early replication of EV71 
( Figure 6B ), indicating that in addition to ERp57, there 
must be other host factors contributing to the inhibitory 
effects of OM on EV71 reproduction. As shown in Table 
II, 10 proteins were down-regulated and 8 proteins were 
upregulated by OM. Whether these proteins contribute 
to the viral inhibition of OM should be investigated 
in future studies. Although several other compounds 
isolated from  Garcinia oblongifolia (e.g., Oblongifolia 
L or P) share similar structure to OM, it antiviral effects 
against EV71 was much weaker (data not shown). 
Further investigating the underling mechanism may help 
us to develop OM derivatives with more potent anti-
EV71 activity. 
 In summary, we showed that OM, an active 
compound isolated from a traditional Chinese herb, 
potently inhibited EV71 infection. By employing 
comparative proteomics studies, we identiﬁ ed that ERp57 
was an effector of OM. Knockdown of ERp57 inhibited 
viral replication through downregulating viral IRES 
activities, whereas ectopic expression of ERp57 increased 
IRES activity and partly rescued the inhibition of viral 
replication by OM. Our results demonstrated that OM 
inhibited the early replication of EV71 partly through 
downregulating ERp57. OM could potentially be further 
developed into a therapeutic drug for treating EV71 
infections, and ERp57 may serve as a target for developing 
host-based antiviral drugs against EV71 infection. 
 MATERIALS AND METHODS 
 Chemicals and antibodies 
 Chemicals were purchased from Sigma (St. Louis, 
MO, USA). Oblongifolin M (OM) was previously identiﬁ ed 
and isolated with purity over 98% [ 27 ]. Commercially 
available antibodies were purchased from different 
companies. Antibody against VP1 was from Abnova (Cat. 
No. PAB7630-B01P), VP2 speciﬁ c antibody was from 
Millpore (Cat. No. MAB979), rabbit polyclonal anti-RCN1 
(Cat No. ab129796), anti-RCN3 (Cat No. 134228), anti-
CALU (Cat. No. ab118308), and anti-ROCK2 (Cat. No. 
ab66320) were from Abcam, anti-ERp57 (Cat. No. H-220) 
and anti- GAPDH (Cat. No. sc-32233) speciﬁ c antibody and 
all the corresponding secondary antibodies were purchased 
from Santa Cruz Biotechnology. 
 Cell culture, virus propagation and compound 
 Rhabdomyosarcoma cells (RD, ATCC accession no. 
CCL-136) were maintained in Dulbecco’s modiﬁ ed Eagle’s 
medium (DMEM) containing 10% (v/v) fetal bovine serum 
(FBS, HyClone) with 100 U/ml penicillin and 100 μg/ml 
streptomycin, at a humidiﬁ ed condition of 5% CO 2 at 37 
°C. EV71 (SHZH98 strain; GenBank accession number 
AF302996.1) [ 30 ,  44 ,  45 ] was propagated on 90% conﬂ uent 
monolayer cells in DMEM with 2% FBS. When about 80% 
of the cells exhibited CPE, culture ﬂ uid was collected, 
centrifuged, ﬁ ltrated and stored in -80°C until use. The 
viral titer was determined by the end-point dilution assay of 
median tissue culture infective dose (TCID 50 ). 
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 CPE assay 
 Antiviral activity of OM was evaluated by CPE 
assays. Approximately 20,000 RD cells per well were laid in 
96-well plate for 24 hours at 37°C to reach monolayer, then 
treated with OM at different concentrations and infected 
by EV71 at MOI of 0.01 or 1 (Supplementary Table S1). 
CPE was monitored from time to time under a phase-
contrast microscope and recorded by a CCD camera. The 
concentration required for the tested compound to reduce 
the EV71-induced CPE by 50% (IC 50 ) was determined 
by using the Forecast function of Microsoft Excel for all 
experiments. Data were shown as mean values with standard 
deviations from three independent assays. Selectivity index 
(SI) is calculated by the ratio of CC 50 to IC 50 . 
 Cytotoxicity test 
 Cytoxicity of OM was evaluated by cell viability 
assays. RD cells (about 20,000 cells) were set in each 
well of a 96-well plate overnight to reach monolayer 
and exposed to serial dilution of OM for 24 hours. Cell 
viability was measured by the MTT method as described 
previously [ 46 ,  47 ]. The CC 50 was calculated. 
 Western blot 
 Cells were lysed in radioimmunoprecipitation assay 
(RIPA) buffer (50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 
1mM EDTA, 1% Triton X-100, 0.1% SDS, 1×Roche 
protease inhibitor cocktail) with occasional vortex. The cell 
lysates were then centrifuged to remove debris at 14,000 
rpm for 20 min at 4°C. The concentration of proteins in the 
lysates was determined by Bradford assay (Bio-Rad). Equal 
amounts of total protein for each sample was loaded and 
separated by 8% to 12% SDS-PAGE and then transferred 
onto polyvinylidene diﬂ uoride (PVDF) membranes 
(Amersham Biosciences). Membranes were blocked with 
5% skim milk in TBST (20 mM Tris-HCl, pH 7.4, 150 mM 
NaCl, 0.1% Tween 20) for 1 h and incubated with speciﬁ c 
antibodies. GAPDH was served as the loading control. 
Target proteins were detected with corresponding secondary 
antibodies (Santa Cruz Biotechnology), visualized with 
a chemiluminescence detection system (Amersham 
Biosciences). Each immunoblot assay was carried out at 
least three times as previously reported [ 44 ]. 
 Real-time RT-PCR 
 The total cellular RNA was extracted using TRIzol 
reagent (Invitrogen) according to the manufacturer’s 
instructions. The virion RNA in the culture media was 
isolated using a viral RNA isolation kit (Qiagen). RNA 
was than reverse transcribed into cDNA using a reverse 
transcription system (Promega). Quantitative reverse 
transcription-PCR (qRT-PCR) was carried out by using 
an ABI 7500 Real-Time PCR system with SYBR Premix 
Ex Taq (Takara). The PCR was set up under the following 
thermal cycling conditions: 95°C for 30 s, followed by 40 
cycles of 95°C for 5 s and 60°C for 34 s. The threshold 
cycle (CT) value was normalized to that of glyceraldehyde-
3-phosphate dehydrogenase (GAPDH) [ 47 ,  48 ]. The qRT-
PCR was performed by using the following primer pairs: 
GAPDH, 5′-GATTCCACCCATGGCAAATTCCA-3’ 
(forward) and 5’-TGGTGATGGGATTTCCATTGATGA-3’ 
(reverse); EV71, 5’-GCAGCCCAAAAGAACTTCAC-
3’and 5’-ATTTCAGCAGCTTGGAGTGC-3’; for 
ERP57, 5’-GTGCTAGAACTCACGGACGA-3’ and 
5’-GCTGCAGCTTCATACTCAGG-3’. All samples 
were run in triplicates, and the experiment was repeated 
three times. The relative mRNA level of each target gene 
was expressed as fold change relative to the value of the 
corresponding control. 
 Two-dimensional gel electrophoresis 
and image analysis 
 RD cells were treated with 30 μM of OM (in DMSO) 
or an equal amount of DMSO for 48 hours. The cells were 
washed with wash buffer (10 mM Tris, 250 mM sucrose, 
pH 7.0) six times to remove salt ions thoroughly, lysed 
with lysis buffer (8 M urea, 2 M thiourea, 2% CHAPS, 
1%Nonidet P-40, 2 mM tributylphosphine, 1× Roche 
Applied Science protease inhibitor mixture, 1× nuclease 
mixture, 1 mM PMSF, 2% IPG buffer), and then left on 
ice for 45 min with occasional vortex. The lysates were 
centrifuged (14,000 g for 15 min) at 4 °C, the supernatants 
were collected and stored at -80 °C until use. Protein 
concentrations were measured by Bradford assay (Bio-
Rad). Isoelectric focusing was conducted with 13-cm 
precast IPG strips (pH 4–7, linear; GE Healthcare) by an 
Ettan IPGphor II IEF System (Amersham Biosciences). 
The IPG strips containing 150 μg of protein samples were 
rehydrated for 10 h at 30 V with 250 μl rehydration buffer 
(8 M urea, 2% CHAPS, 0.4% DTT, 0.5% IPG buffer, 
0.002% bromphenol blue). We then focused the rehydrated 
strips using a stepwise voltage increment program: 500 and 
1000 V for 1 h each and 8000 V afterward until 64 kV-h. 
After IEF, we incubated the isoelectrically focused strips 
in an equilibration buffer (6 M urea, 1% DTT, 2% SDS, 
30% glycerol, 0.002% bromphenol blue, 50 mM Tris-HCl, 
pH 6.8) for 15 min with gentle agitation, then incubated 
the strips for another 15 min in the same buffer containing 
2.5% iodoacetamide without DTT. Then we loaded the 
equilibrated strips onto 12.5% SDS-polyacrylamide gels, 
run at 15 mA/gel for 30 min and then 30 mA/gel until the 
dye fronts reached the bottoms of the gels. We stained the 
gels by modiﬁ ed silver staining, which was compatible with 
MS analysis. Gels were scanned with a calibrated GS-800 
scanner (Bio-Rad), and the intensity of spots was calculated 
and compared by using Quantity One and PDQuest 2-D 
analysis software (version 8.0; Bio-Rad) as described 
previously [ 35 ]. A 2-fold increase/decrease (DMSO-treated 
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versus OM-treated RD cells) of spot intensities was set as 
the threshold for indicating signiﬁ cant changes. 
 MALDI-TOF/TOF MS and MS/MS 
spectrometry analysis 
 Selected spots were manually cut from the gels, 
destained, washed and dried completely by vacuum and 
digested with 10 μg/ml trypsin (Promega) in 25 mM 
ammonium bicarbonate, pH 8.0 for 16–18 h at 37 °C. The 
supernatants containing tryptic peptides were collected. 
We mixed 2 μl of peptide solution with 0.6 μl of matrix 
(6 mg/ml α-cyano-4-hydroxylcinnamic acid in 45% ACN 
and 0.2% TFA) before spotting onto the MALDI plate. 
The samples were applied for mass spectrometric analyses 
by using a MALDI-TOF/TOF tandem mass spectrometer 
Ultraﬂ ex III proteomics analyzer (Bruker Daltonics). 
We obtained mass spectra from 2000 laser shots with an 
accelerating voltage of 20 kV with mass ranges of 700–
4000 m/z in a positive ion reﬂ ectron mode and mass errors 
of less than 100 ppm by using the FlexControl (version 
3.3.108.0, Bruker Daltonics). We obtained MS/MS spectra 
by collecting 3000 laser shots with a default calibration. 
The detected MS/MS peaks were set on a minimum 
S/N ratio ≥3 and cluster area S/N threshold ≥15 with 
smoothing, as described previously [ 49 ]. The information 
from combined MS and MS/MS analysis was applied for 
protein identiﬁ cation search against SwissPort database 
(545388 protein sequences; released on June 23, 2014) by 
the Mascot search engine (version 2.2.04; Matrix Science) 
and BioTools software (version 3.5; Bruker Daltonics). 
The search parameters were deﬁ ned as follows: taxonomy 
of Homo sapiens, trypsin digest with a maximum of 
one missed cleavage, ﬁ xed modiﬁ cation of cysteine 
carbamidomethylation, variable modiﬁ cation of methionine 
oxidation, monoisotopic peptide mass (MH + ), mass range 
unrestricted, pI of 0–14, precursor tolerance of 100 ppm, 
and MS/MS fragment tolerance of 0.5 Da. Before database 
searching, we removed the known contaminant ions from 
the spectra, which correspond to human keratin and trypsin 
autolysis peptides. The top 20 hits for each protein search 
were reported. The protein candidate was reported only 
when it met the maximum number of matched peptides and 
a pI value nearest to the observed value. Each isoform of a 
protein family, which was identiﬁ ed, was considered to be 
a distinct protein for analysis, as described previously [ 49 ]. 
 siRNA synthesis and transfection 
 Speciﬁ c siRNA for ERp57 (siERp57-1) was purchased 
from QIAGEN (Cat. No. SI02654771). An in-house designed 
siRNA (si-ERp57-2) and nonspeciﬁ c siRNA (Scrambled 
siRNA) were synthesized by GenePharma Co. (Shanghai). 
Scrambled siRNA (5′ UUC UCC GAA CGU GUC ACG 
UTT ACG U 3′), which displays no homology to EV71 or 
the human genome, was used as the negative control (NC) 
in this study. RD cells were transfected with siRNAs with 
HiPerFect transfection reagent (Qiagen) according to the 
manufacturer’s instructions. The efﬁ ciency of knockdown 
was measured by qRT-PCR and Western blot assays. 
 EV71 infection, quantiﬁ cation of intracellular 
and extracellular viral genomic RNA 
 RD cells were preincubated with OM for 4 hours 
or transfected with siRNAs for 48 hours, the cells were 
washed twice with phosphate buffered saline (PBS) and 
infected with EV71 at MOI of 1. Time was set to zero after 
adsorption for 1 h. The culture media were removed and 
cells were washed twice with PBS to remove unattached 
virus before adding 0.2 mL of DMEM medium containing 
2% FBS to each well. To quantify the intracellular viral 
RNA or extracellular viral RNA in the virions, total 
RNA was isolated from infected cells or culture media at 
different time-points and further subjected to qRT-PCR 
assays [ 30 ]. 
 Luciferase activity assay 
 Cells (HEK 293) were set in 12-well dishes 
overnight, then transfected with 100 ng of pRF or pIRES 
plasmid. 24 hours post-transfection, cells were treated 
without or with OM at a ﬁ nal concentration of 15 or 30 
μM for 12 hours. The cells were then harvested and cell 
lysates were applied for luciferase assays using a Dual 
Luciferase Assay System (Promega, WI) in accordance 
with manufacturer’s instructions. 
 Statistical analysis 
 Results were expressed as mean ± standard deviation 
(SD). All statistical analyses were carried out with SPSS, 
version 14.0 software (SPSS Inc.). Two-tailed Student’s 
t test was applied for two group comparisons. A p value 
<0.05 was considered statistically signiﬁ cant. 
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